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A B S T R A C T
Obstructive sleep apnea (OSA) is an underdiagnosed common public health concern causing deleteri-
ous effects on metabolic and cardiovascular health. Although much has been learned regarding the
pathophysiology and consequences of OSA in the past decades, the molecular mechanisms associated
with such processes remain poorly deﬁned. The advanced high-throughput proteomics-based technolo-
gies have become a fundamental approach for identifying novel disease mediators as potential diagnostic
and therapeutic targets for many diseases, including OSA. Here, we brieﬂy review OSA pathophysiology
and the technological advances in proteomics and the ﬁrst results of its application to address critical
issues in the OSA ﬁeld.
© 2014 Elsevier B.V. All rights reserved.
1. Obstructive sleep apnea syndrome
Obstructive sleep apnea (OSA) is a common sleep-related breath-
ing disorder which is characterized by recurrent occurrence of partial
or complete closure of the upper airway during sleep, despite
ongoing efforts to breathe [1]. These obstructive events result in in-
terruption of sleep with frequent arousals, loss of REM sleep and
slow-wave sleep, cyclical deoxygenation/reoxygenation, and re-
peated changes in intrathoracic pressure with episodic hypercapnia
[2–4]. Symptoms for OSA are multiple and include snoring, exces-
sive daytime fatigue, apneas while sleeping, morning headaches,
concentration problems, forgetfulness, depression, and sexual dys-
function, among others [1–3]. The majority of patients with OSA
remain undiagnosed since most of them only come to the atten-
tion of a clinicianwhen they complain of daytime sleepiness or when
their bed partners report loud snoring or witnessed apnea epi-
sodes. Epidemiological studies have indicated that OSA affects 6–13%
of the adult population [5] and 1–4% of the pediatric population [6].
The prevalence of OSA is much higher, eg, ≥50%, in patients with
cardiac or metabolic disorders than in the general population [5].
Untreated OSA worsens quality of life and brings long-term con-
sequences, which include cardiovascular disease hypertension,
diabetes, obesity, stroke, depression, and a variety of metabolic dis-
orders. Major risk factors that contribute to OSA pathogenesis include
aging, male sex, and obesity. About 60–70% of patients with OSA
are obese, and obesity is the most common metabolic disorder
[7–10]. The pathophysiological mechanisms of OSA are both complex
and incompletely understood, with differences between aﬄicted
adults as compared to children. OSA is associatedwith adenotonsillar
hypertrophy, craniofacial disorders, lymphoid tissue growth, upper
airway inﬂammation, and/or neuromuscular factors [5,6,11].
The deﬁnitive diagnosis of OSA currently requires an overnight
polysomnographic laboratory-based polysomnography (PSG), which
is expensive and cumbersome [12]. Home unattended study using
a portable sleepmonitor has been encouraged, but 56% of these cases
still require conﬁrmation by laboratory study [13].
The presence and severity of OSA is usually based on PSG, namely
by apnea–hypopnea index (AHI) (consisting of the sum of apneas
and hypopneas per hour of sleep) or by the respiratory distur-
bance index (RDI) (consisting of the sum of apneas, hypopneas and
respiratory effort related arousals per hour of sleep). Adult pa-
tients can be classiﬁed as disease free (AHI < 5/h), mild (AHI ≥ 5,
but < 15/h), moderate (AHI ≥ 15, but < 30/h), or severe OSA
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(AHI ≥ 30/h) [14]. However, the hypopnea deﬁnition criteria are not
consensual, which can result in highly variable AHI values. Conse-
quently, potentially classifying symptomatic patients who would
beneﬁt from treatment are not meeting treatment criteria for OSA.
Moreover, no current established threshold level for AHI exists that
indicates the need for treatment [14–16].
The continuous positive airway pressure (CPAP) is considered the
ﬁrst line treatment in OSA, reducing co-morbidities and associ-
ated societal consequences such as accidents and cognitive
impairment. However, residual sleepiness may persist in some pa-
tients and most chronic consequences of OSA may not be fully
reversed by CPAP treatment [17–20].
Although signiﬁcant progress has been made over the past few
decades, OSA is still a highly underdiagnosed disorder causing del-
eterious effects on human health. Early identiﬁcation of OSA in
patients by a simple and inexpensive point-of-care screening test
is urgently needed to prevent OSA consequences. To better under-
stand the disease complexity, the molecular factors contributing to
the basic mechanisms underlying OSA and OSA bidirectional asso-
ciation with neurocognitive and cardiometabolic dysfunctions must
be elucidated. Identiﬁcation of early and predictive biomarkers of
OSA can be a useful tool in its global strategy, not only at the level
of diagnosis, facilitating timely screening but also at the level of prog-
nosis and therapymonitoring, contributing to a better understanding
and prevention of OSA and OSA-associated disorders. ‘Omics’-
based strategies such as proteomics have the potential to
revolutionize sleep medicine and boost understanding of patho-
physiological pathways of OSA. Proteomics approaches could be
crucial in the identiﬁcation of new OSA diagnostic and prognostic
biomarkers, which could subsequently lead to the development of
novel therapeutic strategies for the treatment of this disease [21].
In this review we are highlighting recent technological ad-
vances in proteomics and presenting an up-to-date overview of
achievements of the proteomics approach in the study of OSA
syndrome.
2. Proteomics-based technologies
Proteins are codiﬁed by genes to play different roles in cell/
tissue/organism (eg, cell-based structures, enzymes, signaling factors,
hormones). There are, however, more proteins, probably up to one
million, than their corresponding codifyinggenes (20,500) inhumans.
Several proteins can be generated from only one gene by alterna-
tive splicing of RNA (the gene messenger) and after translation
proteins can be modiﬁed by up to 400 types of posttranslational
modiﬁcations (PTMs) (eg, phosphorylation, glycosylation, acetyla-
tion), generating different proteoforms with probably different
protein–protein interactions and functions at different cellular/
tissue locations [22]. Alterations in protein sequencing (mutations
in genes) but also in protein abundance and PTMs can modulate/
dysregulate its function and be associatedwith a disease state, drug,
or environmental response.
Proteomics is a large-scale discovery strategy (see Fig. 1), which
refers to the set of technologies applied to explore the proteome,
allowing evaluation of hundreds to thousands of proteins at certain
times and under certain conditions [23]. The beneﬁts of proteomics
are to obtain information regarding changes in protein abun-
dance, protein proteoforms (genetics and PTMs), protein–protein
interactions in a cell, tissue, or organism that can be crucial to un-
derstanding the true molecular phenotype of a disease, which may
also uncover disease biomarkers and disease targets for new drug
development [24].
In the last decade different proteomics-based technologies have
been developed, enabling simultaneous assessment and detection
of large numbers of proteins in biological samples. In disease
biomarker discovery, proteomics have been popular in blood, either
on plasma, serum or blood cells. Proteomics in biological ﬂuids such
as urine, bronchial lavage or aspirate, and tissues like nasal epithe-
lia have also been considered in proteomics study diseases [25,26].
Globally, the protein proﬁling of biological samples using proteomic
approaches is challenging due to the abundance and diversity of pro-
teins. Proteins exhibit an enormous dynamic range of concentration
in biological systems, making identiﬁcation and quantiﬁcation prob-
lematic especially for candidate biomarkers presented at low-
abundance in a complex sample [27]. Proteins cannot be ampliﬁed
as DNA prior to measurement, therefore ultrasensitive techniques
are needed to measure and analyze proteins that are mostly at low
concentrations in a complex mixture or when samples them-
selves are scarce as the clinical samples usually are.
Proteomics technologies have been in constant development.
However, themost popular procedures are two-dimensional gel elec-
trophoresis (2-D gel) and liquid chromatography (LC) for protein
separation, both followed by tandem mass spectrometry (MS/MS)
for protein identiﬁcation (Fig. 1). For either case, proteins should
be ﬁrst extracted from biological samples using compatible bio-
chemical methods, eventually involving fractionation or enrichment
procedures, known by sample preparation [28].
2.1. 2-D gel approach
In the 2-D gel approach the extracted proteins are separated by
their isoelectric point (pI) (ﬁrst dimension) and then by their mo-
lecular weight by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) (second dimension). After electropho-
resis, gels are stained (eg, Coomassie Blue, silver staining) and the
developed 2-DE pattern images showing thousands of proteins are
captured by a scanner and analyzed by computer assistance for quan-
tiﬁcation. The protein spots showing signiﬁcant differences (lower
or higher abundance or presence or absence) between disease and
control are excised from gels for further MS identiﬁcation. The limi-
tations of 2-D gel are associated with its inability to resolve all
proteins present in a sample due to differences in protein solubility
or hydrophobicity, wide range in protein expression levels (high-
versus low-abundance proteins), presence of too basic or acidic pro-
teins that exceed the pH range capacity, or SDS-PAGE upper or lower
molecular size gel limits. Difference gel electrophoresis (DIGE) [29]
is an improved modiﬁcation of 2-D gel, in which controls and dis-
eased samples pre-labeled with different ﬂuorescent CyDyes can be
analyzed on a single gel together with an internal standard (the sum
of all disease/control CyDye-labeled samples in one), reducing ex-
perimental variation and increasing sensitivity and protein detection
by up to ﬁve orders of magnitude [30]. The 2-D gel patterns can be
visualized for each CyDye-labeled sample (disease/control) using
speciﬁc ﬂuorescence scanners for further computer-based quanti-
ﬁcation and spot excision for MS identiﬁcation (Fig. 1).
2.2. Shotgun proteomics (LC/MS/MS)
In shotgun proteomics, the extracted proteins are digested, typ-
ically with trypsin, and the produced peptides separated by LC such
as strong anion exchange combined with reverse-phase chroma-
tography and fractions analyzed by an online tandem mass
spectrometer for peptide and protein identiﬁcation (Fig. 1). Initial-
ly applied for full identiﬁcation and characterization of proteomes,
the shotgun approach was soon extended to quantitative and com-
parative studies in biomarker discovery, due to the introduction of
stable isotope labeling strategies like ICATs, stable isotope label-
ing with amino acids in cell culture (SILAC), and more recently,
isobaric tags such as iTRAQ and tandem mass tags (TMT) for rela-
tive and absolute quantiﬁcation [28]. In brief, these reagents use ‘tags’
of different masses to label differentially proteins from control or
disease proteins, which are then pooled and analyzed via MS to
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identify and quantify peptides and hence proteins. Multiplexed anal-
ysis allowing differentially labeled samples being simultaneously
measured by MS is the main advantage of these stable-isotope-
labeled methods. The limitations are related to incomplete labeling,
variability in chromatographic runs, complex sample preparation,
need for a higher protein concentration and, not least, higher costs.
Due to these shortcomings, label-free quantitative proteomics have
become an attractive method. This is usually based on a spectral
counting approach, which implies a counting and comparison of the
number of fragment-ion spectra (MS/MS) acquired for pipettes of
a given protein based on the empiric observation that higher abun-
dance of a particular protein in a sample is related to higher number
of corresponding peptides MS/MS spectra [31,32]. Although label
or label-free LC–MS/MS methods still suffer from some issues with
reproducibility and dynamic range, these methods have been shown
to provide increased proteome coverage compared to 2-D gels. Nev-
ertheless, comparative studies between 2DE-MS and LC–MS/MS have
shown limited overlapping among proteome identiﬁcations sug-
gesting the complementary nature of these approaches [33].
Although less popular than the 2D-gel or LC/MS/MS approaches,
surface enhancer laser desorption ionization time of ﬂight MS tech-
nology (SELDI-TOF) and capillary electrophoresis coupled MS (CE–
MS) have been also used for disease biomarker discovery, including
OSA.
2.3. SELDI-TOF
SELDI-TOF combines retention of proteins by adsorption or af-
ﬁnity chromatography on a solid-phase protein chip surface that
can be further analyzed by MS. Initially, this technology only
Fig. 1. Discovery-based strategy for candidate biomarker of Obstructive Sleep Apnea. In discovery-based proteomics approach, the 2D-difference gel electrophoresis (2-DIGE)
and liquid chromatography/tandem mass spectrometry (LC/MS/MS) (Shotgun) are the most popular methodologies to identify disease candidate biomarkers. The proteins
identiﬁed as differentially abundant (up/down and present/absent) in disease are veriﬁed by orthogonal methodologies (other than those used in the discovery phase) before
proceeding to the next validation phase in a larger cohort of patients and translation into clinical application.
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provided MS spectra proﬁling without protein identiﬁcation. New
ProteinChip interface coupled to tandem mass spectrometer was
recently developed allowing direct sequencing of peptides <6000 Da.
However, further conﬁrmation by antibody-based methods (ie,
western blot or ELISA) or antibody pull-down with subsequent de-
tection by SELDI-TOF-MS is still recommended [34] for conﬁdent
protein identiﬁcation.
2.4. CE–MS
In CE–MS, instead of separations by LC, protein extracts, usually
body ﬂuids, are separated by CE prior to MS identiﬁcation. Al-
though interfaced with MS, direct protein sequencing could be a
challenge due to limited loading capacity of the CE [35].
2.5. Target proteomics
In contrast to those above technologies which operate on an un-
biased mode discovering what proteins can be detected and
quantiﬁed in a sample, an alternative method, known as target
proteomics, has been developed as a biased approach testingwhether
a given protein or a set of proteins is measurable in a particular
sample [36–38]. This target proteomics is based on the selected-
or multiple-reaction-monitoring (SRM/MRM) technology, in which
themass spectrometer is programmed to pre-select and analyze spe-
ciﬁc peptides generated from proteins of interest. This requires that
relevant proteins for a given sample or disease be determined a priori,
which can be a limitation for biomarker discovery studies. Target
proteomics has been used very successfully for veriﬁcation/
validation of the data obtained in the discovery phase (see below).
2.6. Veriﬁcation phase
Whatever the proteomic platform approach used, hundreds to
thousands of biomarker candidates can be generated but few of them
may warrant assessment in a time-consuming and costly large-
scale clinical validation trial (Fig. 1). In a biomarker development
pipeline, experimental design, prioritization, and veriﬁcation are
crucial early stages in the selection of the most promising candi-
dates for clinical validation and translation to a speciﬁc clinical
application [39,40].
A better understanding of the disease state and the putative pro-
teins or pathways involved in the process, taking into account their
functional relevance to the cell/tissue or bioﬂuid where they were
identiﬁed as altered during the discovery phase, would help to
developmeaningful criteria for prioritizing candidates for the further
validation stage [26,40]. Methods based on immunoaﬃnity such as
western blotting, ELISA, immunocyto/histochemistry, and more re-
cently, SRM-based methods are the most popular in the veriﬁcation
stage (also referred to as assessment of performance when any can-
didates are veriﬁed by an orthogonal method, ie, other than that
one used in the discovery phase) (Fig. 1). The relevance of the ver-
iﬁcation stage is reﬂected by the fact that for many proteomics
journals of high impact, it is a mandatory requirement for report-
ing of clinical biomarker studies.
To help improve the overall success of the biomarker discovery
pipeline, an important statistical framework for the design
of biomarker discovery and veriﬁcation studies was recently gen-
erated from the workshop entitled “Experimental Design
Considerations in Research Studies Using Proteomic Technolo-
gies” with the participation of U.S. Food and Drug Administration
(FDA) [41]. The ultimate goal of this statistical approach is to set
clinical relevance and appropriate biospecimen sample size for dis-
covery and veriﬁcation stages prior to the clinical validation stage,
contributing to making protein biomarker discovery from the bench
to the clinic quicker and more successful. However, there is still a
need for computational methods and algorithms allowing for con-
sistent analysis and interpretation of proteomic data using statistical
principles.
2.7. Mass spectrometry
Mass spectrometry measures the mass-to-charge ratio (m/z) of
ionized molecules such as proteins/peptides and produces spectra
containing m/z values versus intensity count. Matrix-assisted laser
desorption/ionization (MALDI) and Electrospray ionization (ESI) are
the two most common techniques to volatize and ionize the pro-
teins or peptides for subsequentmass spectrometric analysis. MALDI-
MS is mostly used to analyze relatively simple peptide mixtures (eg,
from 2-D gel protein spots). Samples are deposited on aMALDI plate,
left to dry with a crystalline matrix to be ionized via laser pulses.
ESI ionizes the analytes out of a solution coming from an LC system.
Integrated LC systems with ESI-MS systems (LC–MS) are preferen-
tially used for analysis of complex samples. There are different types
of mass analyzers, with different advantages/disadvantages, such
as time-of-ﬂight (TOF), ion trap, quadrupole, Fourier transform ion
cyclotron (FT-MS), and orbitrap [42].
Fig. 2 outlines a frequently used strategy (bottom-up proteomics)
for identifying potential novel biomarkers. The tryptic peptides gen-
erated from protein digestion are separated by LC and online injected
into themass spectrometer, which employs two stages of mass anal-
ysis (tandem MS) to identify peptides used subsequently to infer
protein identiﬁcation. Peptide sequencing is achieved by matching
the tandem mass spectra derived with theoretical tandem mass
Fig. 2. Simpliﬁed scheme of a typical mass spectrometry (MS)-based strategy to identify potential biomarkers (bottom up proteomics). In the ﬁrst step proteins (A) are
digested (B) to peptides (C) usually by trypsin (which predominantly cleaves at the carboxyl side of lysine “K” and arginine “R” except when either is followed by proline).
(D) The tryptic peptides generated from protein digestion are injected into a liquid chromatography system (for peptide separation) online coupled with a mass spectrometer,
which employs two stages of mass analysis (tandem MS, MS/MS). (E) The ﬁrst stage is MS which corresponds to mass scans of peptides eluted at different time points from
the LC system. (F) In the second stage, some peptides, usually the most abundant, are automatically selected for fragmentation generating MS/MS spectra. Mass differences
between peaks in the MS/MS spectrum can be directly correlated to amino acid residues and a short peptide sequence can be obtained. Protein and peptide identiﬁcation
is achieved by computer-based matching of the experimental tandem mass spectra with the theoretical tandem mass spectra generated from in silico digestion of protein
sequence databases.
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spectra generated from in silico digestion of a protein sequence da-
tabase (Fig. 2). Protein inference is often complicated by the fact
that many tryptic peptides are shared among proteins. Moreover,
mass accuracy used for database-dependent search, the speciﬁc se-
quence database used for the search, the ﬁltering criteria such as
minimum number of peptides identiﬁed, and False Discovery Rate
(FDR) cutoff can also dramatically change the proteins and pep-
tides identiﬁed in the ﬁnal report and can be a reason for lost
information and low reproducibility when validation is per-
formed in another laboratory that uses a different data analysis
pipeline [43,44]. Besides protein inference, the protein state is
another issue in bottom-up proteomics, which often does not provide
accurate information on the site location of PTMs, and even if the
site location is well determined the quantitative value cannot be
directly linked to quantitative values of protein states [45]. Based
on literature and our preliminary data, we hypothesize that spe-
ciﬁc PTMs could be involved or linked to OSA. We already identiﬁed
several oxidation and nitrosylation products that, in general, display
a regulatory difference between snorers and OSA patient groups. An
example of a nitrosylated peptide from hemoglobin subunit alpha
identiﬁed by MS/MS is provided in Fig. 3. This was accomplished
by using state-of-the-art mass spectrometers and by using an open
search for modiﬁcations when matching MS/MS spectra against se-
quence databases [46–48].
3. Proteomics in obstructive sleep apnea syndrome
Pathophysiological mechanisms underlying OSA are still elusive.
Researchers endeavor to understand why patients with similar se-
verity of OSA often have signiﬁcantly different clinical manifestations
and co-morbidities. Which mechanisms distinguish OSA in the pe-
diatric and adult populations? How should the adequacy of treatment
response be monitored? Studies on sleep deprivation in animal
models [49–51] and OSA syndrome in human cohorts using
proteomics approaches imply the great potential of this emerging
discipline to impose scientiﬁc dilemmas of etiology, diagnosis, and
treatment of OSA. Herein, we review the proteomics studies per-
formed so far in children (Table 1) and adult (Table 2) populations,
in an attempt to discover biomarkers for improving diagnosis, treat-
ment, and a better understanding of OSA pathology.
Shih and Malhotra identiﬁed properties of an ideal biomarker
for OSA, which should be highly sensitive, speciﬁc, dose-responsive,
and correlate with the severity of the disease. The biomarker or set
of biomarkers should serve as a measure of adequacy of therapy
and be involved in the causal pathway, therefore being useful for
predicting outcome [63,64].
The pioneering work of Shah et al. (2006) on serum proteome
proﬁling in pediatric OSA patients is in concordance with criteria
for an ideal OSA biomarker [52]. They identiﬁed three differently
expressed proteins which could distinguish OSA versus OSA-free pa-
tients with 93% sensitivity and 90% of speciﬁcity [52] (Table 1). In
this study the SELDI-TOF MS approach was used for analysis. After
MS analysis, proprietary classiﬁcation algorithms were applied, in-
volving three nodes with distinct masses. Three discriminatory peaks
of 5896, 3306, 6068 Da distinguished OSA from controls with 93%
sensitivity and 90% speciﬁcity. A protein biomarker candidate cor-
responding to a peak at 5896 Da was identiﬁed as osteocalcin [52]
(Table 1). Increased serum osteocalcin was previously observed in
diseases with increased bone turnover and in children with growth
retardation. Since growth retardation is a frequent observation in
children with OSA, authors suggested that the increase of osteocalcin
in these patients may compensate for the growth deceleration
imposed by the episodic asphyxic events associated with recur-
rent upper-airway obstruction [52].
Fig. 3. Annotated raw tandemmass spectrometry (MS/MS) spectrum (real example of Fig. 2F) of the peptide “TyFPHFDLSHGSAQVK nitrosylation” from hemoglobin subunit
alpha with tyrosine nitrosylated. Protein extracts of OSA erythrocyte cells were digested by trypsin followed by liquid chromatography (LC)–MS/MS analysis. The peptide
“TyFPHFDLSHGSAQVK nitrosylation” was observed at charge state z = +3 in scan number 24071 (which corresponded to a speciﬁc elution time from the LC system) and at
621.6344 m/z. The x-axis is mass over charge (m/z) for fragment ions and the y-axis is intensity counts. Theoretical fragment ions that match the observed fragments in the
MS/MS spectrum are annotated with blue text. Amino acid residues can be correlated to mass difference between peaks. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
441A. Feliciano et al./Sleep Medicine 16 (2015) 437–445
Searching for a non-invasive biomarker test for OSA, Krishna et al.
have used urine as a source for identifying new biomarkers [53].
They performed a study in a pediatric population with a mean age
of 6.8 years. The discrimination criterion for stratiﬁcation in the OSA/
non-OSA groupwas AHI (AHI < 1/h – control; AHI > 5/h – OSA group).
For proteomics analysis 2D-PAGE and the MALDI-TOF-TOF MS ap-
proach was used. After an image analysis of 22 urine samples, ﬁve
spots were selected for further analysis based on intensity differ-
ences between two examined groups. Authors pin-pointed ﬁve
identiﬁed proteins (p < 0.05, protein score >67): gelsolin, percolan,
albumin, tropomyosin, and immunoglobulin. Krishna and co-
authors found a subset of proteins that markedly have different
expression in the urine of pediatric patients with sleep-disordered
breathing. Based on these results, the authors suggested the renal
system as another end-organ target for OSA. Validation of these
ﬁnding as well as future prospective studies on larger cohorts is re-
quired to conﬁrm their ﬁndings [53].
Gozal et al. also conducted extensive 2D-DIGEs and MALDI-TOF-
TOF MS studies of urinary proteome aiming to extend their
preliminary ﬁndings in pediatric OSA [54]. The authors performed
extensive 2D-DIGE experiments, 150 in total, to ascertain
reproducibility and consistency of results. The total number of de-
tectable protein spots ranged from 713 to 789 in all urine samples,
of which 23 were markedly differently expressed across all gels.
About 12 novel non-redundant proteins were identiﬁed with a high
level of conﬁdence. Image analysis showed that three of the iden-
tiﬁed proteins were under-expressed while nine were overexpressed
in OSA patients. Six of these 12 identiﬁed candidate biomarkers were
validated by ELISA (Kallikrein, uromodulin, urocortin-3) and western
blotting (tenascin, tribbles homolog-2, zinc ﬁnger protein 81). ROC
analysis performed for uromodulin, urocortin-3, orosomucoid-1, and
kallikrein shows high sensitivity and speciﬁcity in the identiﬁca-
tion of OSA. The authors suggested future larger prospective studies
to validate the abovementioned ﬁndings.
Snow and collaborators used SELDI-TOF MS to proﬁle proteins
in the ﬁrst morning void urines from children with OSA [55] and
habitual snorers. Using the supervised linear discriminative analysis
of the normalized peaks obtained from urine protein proﬁling, two
distinct proteins among the OSA group were discovered, charac-
terized by molecular weights of 4382 Da and 4640 Da. The most
plausible and relevant preliminary identiﬁcation of the putative
biomarker pointed toward urocortin (UCN), which is the prototype
Table 1
Proteomics studies conducted in children with obstructive sleep apnea (OSA).
Reference Proteomics approach Sample Main ﬁndings Orthogonal veriﬁcation
Shah et al. [52] SELDI-TOF Children/serum
(20 OSA/20 controls)
↑3 protein peaks (5896, 3306, 6068 Da) with
93% sensitivity/90% speciﬁcity
Peak 5896 Da identiﬁed as osteocalcin
No
Krishna et al. [53] 2D-PAGE/MALDI/TOF/TOF Children/urine
(11 OSA/11 controls)
↑Gelsolin, perlecan, albumin, tropomyosin and
immunoglobulin
No
Gozal et al. [54] 2D-DIGE Children/urine
(60 OSA/60 controls)
12 proteins identiﬁed modulated
↑Uromodulin, urocortin-3, orosomucoid-1 and
↓kallikrein with high sensitivity/speciﬁcity in
ROC analysis
ELISA (↑kallikrein, uromodulin and
urocortin-3)
WB (↑tenascin, tribbles homolog-2 and
↓zinc ﬁnger protein 81)
Snow et al. [55] SELDI-TOF Children/urine
(30 OSA/25 controls)
↑Urocortins No
2D-DIGE, two-dimensional difference gel electrophoresis; 2D-PAGE, two-dimensional polyacrylamide gel electrophoresis; MALDI, matrix-assisted laser desorption/
ionization; SELDI, surface enhancer laser desorption ionization; TOF, time of ﬂight.
Table 2
Proteomics studies conducted in adults with obstructive sleep apnea (OSA).
Reference Proteomics approach Sample Main ﬁndings Orthogonal veriﬁcation
Kim et al. [56] 2D-PAGE (silver staining)/
MALDI/TOF/TOF
Adults/serum depleted
for albumin and IgG
(40 OSA/34 controls)
↑Haptoglobin, apolipoprotein M (apoM) and four
complement components, ↓paraoxonase-1 (PNO1)
and α-ferrous-carbonmonoxy
WB (↑haptoglobin,apoN
and ↓PNO1) haptoglobin
decreased after CPAP
Jurado Gámez et al. [57] 2D-PAGE (sypro-ruby
staining)
Adults/serum depleted by
Proteominer kit (24 OSA/8
controls)
10 spot proteins modulated (3 ↑ and 7↓)
No MS identiﬁcation
No
Jurado Gámez et al. [58] iTRAQ/MALDI/TOF/TOF Adults/sera (30 OSA
mild/moderate/severe/ 10
controls)
30 proteins identiﬁed modulated (19 ↑ and 11 ↓)
↓C4BPalpha and thrombospondim in all three OSA
groups; ↓vitronectinm clusterin isoform2, ApoE and
antithrombin in mild and moderate OSA
13 ↑ in mild, 7↑ in moderate and 5 ↑in severe OSA.
Alterations in lipidic and vascular and metabolic
pathways are particularly involved
No
Jurado Gámez et al. [59] iTRAQ/MALDI/TOF/TOF Adults/sera
(11 OSA/11 controls)
↑PRO0684, short immunoglobulin lambda VLJ and
kininogen HMW precursor involved in
inﬂammation, immune response and coagulation
No
Jurado Gámez B et al. [60] 2D-PAGE (sypro-ruby
staining)/MALDI/TOF/TOF
Adults/sera
(37 OSA/18 controls)
↑Haptoglobin
↓↓Albumin and serotransferrin
No
Shinohara et al. [61] LC/MS/MS (LTQ
instrument)
Adults/plasma (6 severe
obese OSA/6 controls
non-obese)
26 proteins modulated (12 ↑ and 14↓)
↑Complement proteins, ceruloplasmin, amyloid
P-component associated with inﬂammation and
immunomodulation
No
Seetho et al. [62] CE–MS Adults/urine (61 obese
OSA/31 obese non-OSA)
24 peptides (some of these generated from collagens
and ﬁbrinogen alfa) were candidates for differential
distribution
No
CE, capillary electrophoresis; 2D-PAGE, two-dimensional polyacrylamide gel electrophoresis; LC, liquid chromatography; MALDI, matrix-assisted laser desorption/
ionization; MS, mass spectrometry; TOF, time of ﬂight.
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of an important family – the corticotrophin-releasing hormone-
related peptideswhichmediate response to stress aswell as stress-
coping processes.
According to our knowledge, Kim and co-workers have been the
ﬁrst to analyze serum proteome of OSA adult subjects [56]. Criteria
of OSA severity were based on AHI and co-related clinical symp-
toms. After 3–5 months on CPAP therapy, the serum of 10 subjects
of OSA and controls was subjected to proteomics analysis. Differ-
ently expressed proteins were detected after previous separation
of samples using silver-stained 2D-PAGE, followed by image anal-
ysis. Protein abundance per spotwas elucidated by integrating pixel
densities and correcting for the background. Spots which showed
equal or higher than two-fold alteration in protein expressionwere
considered for further MS analysis. In total, nine spots were found
to bemarkedly up- or down-regulated in patientswithOSA (Table 2).
After excision, these protein spots were analyzed by MALDI-TOF-
TOF MS, and identiﬁed using ProFound program. Except serum
paraoxonase (PON1) and alpha-ferrous-carbonmonoxy, all identi-
ﬁed proteins were highly abundant. These ﬁndings were validated
bywestern blotting andELISA techniques for thehaptogolobin, PON1,
and apo M [56]. It is important to note that levels of haptoglobin
were signiﬁcantly higher in all patients with OSA. However, after
CPAP treatment the level of haptoglobin was markedly decreased.
This ﬁnding implies haptoglobin as a putative serum biomarker for
the follow up CPAP treatment in OSA patients. This behavior was
not followed by the other two validated proteins. Haptoglobin and
apo M were found to be independently associated with AHI [56].
Jurado Gámez et al., in 2010, applied sypro-ruby-stained 2D-
PAGE for the analysis of serum protein signature of patients with
different stages of OSA syndrome [57]. Patients were stratiﬁed by
AHI into four groups – controls andmild, moderate, and severe OSA,
each constituted by eight individuals. After image analysis, optical
density of the protein spots which were three-fold changed com-
pared to corresponding spots in control samples were considered
as putative biomarkers. In total 10 protein spots met this criteria,
of which three were overexpressed, while seven were under-
expressed compared to controls. Although, none of these spots were
further identiﬁed by MS, this preliminary work showed for the ﬁrst
time that distinct levels of a group of proteins can correlate with
the severity of OSA. From this preliminary study, the authors moved
on to apply a more powerful technique, iTRAQ isobaric tags asso-
ciated withMALDI-TOF-TOF, aiming to obtain deeper knowledge and
identify differently expressed proteins [58]. Researchers con-
ducted a prospective observational study designed as described
earlier [57]. To minimize any variance in ﬁndings, this study in-
cluded only males referred to the Sleep Unit. Subjects were assigned
into groups according to AHI: controls and mild, moderate, and
severe OSA patients. Morning serum was collected and pooled ac-
cording to OSA severity and control groups using equimolar protein
contributions from each subject. Samples were prepared for
proteomic analysis [58], labeled with iTRAQ4plex tagging kit, and
analyzed by MALDI-TOF-TOF MS. Database searches (Protein Pilot)
resulted in identiﬁcation of 103 proteins of which 30 showed
differences in expression between OSA and control groups (11 under-
and 19 over-expressed) (Table 2). The authors highlighted that com-
plement component 4-binding alpha and thrombospondin precursor
proteins were signiﬁcantly under-expressed in all OSA groups, while
the rest of the underexpressed proteins were only assigned to the
groups with mild and moderate OSA when compared to control.
Among the overexpressed proteins it should be emphasized that
ﬁbronectin, Apo B100, immunoglobulin heavy constant alpha 1, and
Apo D showed progressive severity-related ratio increases in OSA
groups compared to control. Cellular ﬁbronectin may be a protein
marker for the activation of endothelial cells. Elevated ApoB-100
is associated with an increased risk of cardiovascular disease. Ce-
ruloplasmin interacts with other proteins in the inﬂammatory
pathways. Although, none of these proteins were veriﬁed by or-
thogonal techniques, the authors suggested that these sets of
modulated proteins can be potentially related to several metabol-
ic pathways, such as the lipid and vascular metabolic pathways,
suggesting that OSAmay facilitate the onset and progression of ath-
erogenesis. A number of proteins involved in coagulation,
inﬂammation, and lipid metabolism may indeed interact in the
context of OSA to affect lipid and vascular pathways. Jurado Gámez
and collaborators concluded that protein expression correlates with
severity of disease, but at the same time provides relevant mech-
anistic information.
Further, Jurado Gámez et al. designed a prospective pilot study
aiming to identify differences in protein expression in patients with
mild OSA syndrome [59]. Morning serum of individuals was ac-
quired and processed for proteomic analysis. Peptide tryptic digests
were labeled with isobaric tags (ITRAQ) and submitted to analysis
by MALDI-TOF-TOF MS using ProteinPilot software for peptide iden-
tiﬁcation. Proteins which had iTRAQ ratio >1.3 related to control,
were considered as overexpressed and three proteins fulﬁlled this
criterion: PRO0684, short immunoglobulin lambda VLJ, and kinino-
gen HMWprecursor. However, these results are preliminary and not
validated by orthogonal techniques. Further study in a bigger cohort
without gender discrimination is needed to conﬁrm these ﬁndings.
Jurado-Gámez et al. designed another prospective study using
2-PAGE to identify differentially expressed proteins in an OSA pop-
ulation with an age range between 30 and 70 years [60]. They
identiﬁed haptoglobin as overexpressed in OSA. Haptoglobin has
been associated with cardiovascular risk in patients with OSA [65].
Two under-expressed spots were identiﬁed as albumin and
serotransferrin, suggesting that these proteins can facilitate a de-
crease of the antioxidant defenses in OSA. Albumin is the most
abundant protein in the circulatory system. Low abundance of serum
albumin can be related with high levels of urinary albumin excre-
tion observed in OSA patients, even in the absence of associated
hypertension or diabetes [66]. Albumin has an antioxidative activ-
ity due to its capacity to bind ions and to eliminate free radicals [67].
Serotransferrin is a glycoprotein produced and metabolized in he-
patocytes and the main function is iron transport in blood allowing
an antioxidant capacity [60].
Shinohara and co-workers examined plasma proteomic proﬁl-
ing in severe OSA patients with obesity (BMI > 30 kg/m2) and non-
OSA patients without obesity (BMI < 30 kg/m2) [61]. In this work,
the shotgun approach was used in protein analysis. A total of 19,745
components were tracked and differentially quantiﬁed. Many pro-
teins regarding inﬂammation and immune response, including
complement proteins, two acute-phase reactants ceruloplasmin and
serum amyloid P-component, were found to be highly expressed
in obese severe OSA patients (Table 2). The authors concluded that
protein changes responsible for immune modulation and inﬂam-
mationmay be a feature of OSA patients. The authors acknowledged
limitations of the study due to small sample size. However, they high-
lighted ﬁndings of the study, which revealed that a high percentage
of differently expressed proteins are associated with modulation of
immune system and inﬂammation, thus suggesting that these
mechanisms are involved in OSA syndrome. Further veriﬁcation and
validation of these ﬁndings will be necessary to conﬁrm their par-
ticipation in the pathophysiology of OSA.
During revision of this manuscript we came across the work of
Seetho et al. reporting urinary proteomics proﬁling in OSA and non-
OSA obese adult patients using CE–MS technology [62]. The data
showed 24 peptides that were differentially abundant (p < 0.01)
between patient groups, although these differences did not reach
signiﬁcance after adjustment formultiple statistical testing to account
for false positives (false discovery rate). Some of these peptides origi-
nated from collagens and ﬁbrinogen alpha. No further veriﬁcation
experiments were performed.
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4. Conclusion
Heterogeneous studies in sampling, relatively small cohorts, non-
standardized diagnostic methods, lack of veriﬁcation and validation
data are the main drawback of proteomics studies made to date in
OSA patients. At this stage, these studies should be considered very
preliminary. Nevertheless, the results obtained so far are tremen-
dously encouraging for showing signiﬁcant differences in OSA
proteome proﬁle which, once validated, may be considered for trans-
lation into a proteomics-based noninvasive testing for OSA screening,
diagnosis, or prognosis. These ﬁrst studies opened new perspec-
tives for future proteomic evaluation in OSA patients, orienting the
design of future proteomics studies. Those should be undertaken
as much as possible in bigger cohorts of adults/children with OSA
presenting different levels of severity and co-morbidities. Proteomics
analysis in different biological samples (other than serum or urine),
such as plasma, blood cells (eg, red blood cells, macrophages) or
even nasal epithelia, should also be considered in future studies.
In terms of proteomic technology, the application of complemen-
tary approaches such as 2D-DIGE with higher-throughput
technologies such as LC–MS/MS using a new generation of mass
spectrometers (eg, orbitrap system) and/or a target proteomics ap-
proach (SRM assay) will certainly increase markedly the sensitivity/
speciﬁcity for biomarker identiﬁcation in OSA. A veriﬁcation step
using orthogonal technologies should always be considered as a
crucial step to better select themost promising candidates for further
clinical trial validation. Since OSA is a disorder occurring during sleep
time, evaluating proteomic signature before, during, and after sleep
in persons with and without CPAP therapy could give an answer
regarding molecular pathways and metabolic alterations in persons
with OSA. Such changes will be at least partly a consequence of
chronic intermittent hypoxia and sleep fragmentation that occur
during the sleep.
In summary, much investigation remains to be done before we
can deﬁne potential biomarkers for OSA with impact on diagnosis,
disease management, and prognosis of this prevalent disorder. Re-
search efforts could then be directed at identifying novel treatment
interventions that not onlymodify thebiomarker levels but also affect
the pathophysiology of the disease and its clinical outcome.
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